Saredutant (SR 48968) is a neurokinin-2 antagonist drug being developed as an antidepressant and anxiolytic by Sanofi-Aventis.
Investigated for use/treatment in depression and anxiety disorders.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.